Drug Profile
BSG 005
Alternative Names: BSG 005G; BSG-005Latest Information Update: 04 Jan 2023
Price :
$50
*
At a glance
- Originator Greenlight Clinical; Norwegian university of science and technology; Nucleus Network; Select Pharma; SINTEF Materials and Chemistry
- Developer Biosergen; Greenlight Clinical; Nucleus Network; Select Pharma
- Class Antifungals; Macrolides; Polyenes
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Mycoses
Highest Development Phases
- Phase I Mycoses
Most Recent Events
- 16 Jun 2021 Biosergen plans phase II trials for Mycoses in 2022 and 2023 (Biosergen pipeline, June 2021)
- 16 Jun 2021 BSG 005 is still in preclinical trials for Mycoses in Norway
- 16 Jun 2021 Early research in Mycoses in Norway (PO) prior to June 2021 (Biosergen website, June 2021)